Stock report · Delisted · Nasdaq
NLS Pharmaceutics AG (NLSP)
0.76USD Delisted Final close · Oct 30, 2025
NLSP no longer trades. NLS Pharmaceutics AG was delisted from the Nasdaq in October 2025.
All prices on this page are historical. The last trade was on October 30, 2025, at $0.76.
NLSP stock price history
Final trading statistics
- Final close
- $0.76
- Final trading day
- Oct 30, 2025
- Market cap at delisting
- $3.97M
- Shares outstanding
- 5.21M
- Final 52-week range
- $0.74 – $4.74
- Avg. volume (final 3 mo.)
- 1,440,394
- All-time high
- $2340.00 · Mar 2021
- All-time low
- $7.40 · Oct 2025
- Return since IPO
- -99.3%
- Beta
- 0.13
- Book value / share
- $6.79
- Price / book
- 0.11
About NLS Pharmaceutics AG
NLS Pharmaceutics AG was a clinical-stage biopharmaceutical company developing therapies for rare and complex central nervous system disorders. Its focus areas were narcolepsy, idiopathic hypersomnia and other rare sleep disorders, as well as ADHD and other neurodevelopmental conditions.
Lead candidates were Quilience for narcolepsy and Nolazol for ADHD. Other programs included NLS-4 for Long-COVID fatigue, NLS-3 for ADHD, NLS-8 for scopolamine-induced amnesia, and NLS-11 and NLS-12, which combine norepinephrine and dopamine reuptake inhibition with muscarinic receptor blocking.
It licensed mazindol for ADHD from Pegasus Advanced Research. Incorporated in 2015 and based in Zurich, Switzerland, the company was delisted from the Nasdaq in October 2025, with the last trade on October 30, 2025 at $0.76.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zurich
- Employees
- —
- IPO date
- January 29, 2021
- Delisted
- October 30, 2025
- SEC CIK
- 1783036
NLS Pharmaceutics AG financials before the delisting
The last 5 fiscal years NLS Pharmaceutics AG reported as a public company, fiscal year ending December.
NLSP revenue and net income
NLSP earnings per share
NLSP annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$2.0M | — |
| FY2023 | $0.00 | −$12.2M | — |
| FY2022 | $0.00 | −$16.5M | — |
| FY2021 | $0.00 | −$11.9M | −$1.66 |
| FY2020 | $0.00 | −$2.9M | −$0.92 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
NLS Pharmaceutics AG stock FAQ
What happened to NLS Pharmaceutics AG stock?
NLS Pharmaceutics AG was delisted from the Nasdaq in October 2025. The final close was $0.76 on October 30, 2025.
Can I still buy NLSP stock?
No. NLSP is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on October 30, 2025.
What was the last price of NLSP?
NLSP last closed at $0.76 on October 30, 2025, which valued the company at about $3.97M.
How did NLS Pharmaceutics AG do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, NLS Pharmaceutics AG reported revenue of $0.00 and net income of −$2.0M.
When did NLS Pharmaceutics AG go public?
NLS Pharmaceutics AG shares started trading on January 29, 2021.
NLSP no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.